Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...